anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

129,361-129,420 of 319,975

filter-aware
226
The slide uses a direct quote from a Lancet letter to undermine the credibility of the HARMONY 1 trial investigators.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
227
The slide highlights a discrepancy between the reported trial results and the underlying patient-level data regarding dosage and efficacy.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
228
The slide highlights a recurring methodological inconsistency across multiple clinical trials, suggesting regulatory oversight failure.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
229
The slide highlights a specific regulatory failure/contradiction regarding the acceptance of post-hoc analysis in clinical trials.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
230
The slide uses a redacted document image to illustrate the lack of transparency in the FDA's review process compared to the EMA's.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
231
The slide uses a 'villain' framing for the FDA reviewer's oversight.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
232
The slide highlights a discrepancy between raw ESS scores and adjusted LS means, accusing the sponsor of data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
233
The slide uses a combination of a pie chart and two tables to substantiate claims of trial design flaws.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
234
The slide details three specific statistical and methodological reasons for the FDA's rejection of the HARMONY 1 study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
235
The slide uses a strong, accusatory tone ('sycophancy', 'red flags') to frame the FDA's regulatory process as flawed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
236
The slide uses a pie chart to visualize the geographic concentration of trial participants, specifically pointing out the high percentage in Russia to support a claim of data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
237
The slide uses a 'villain' framing to discredit the reliability of clinical data originating from Russia and Eastern Europe.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
238
The slide highlights a discrepancy between the trial paper's log-scale chart and the actual linear-scale data, suggesting data manipulation or misleading presentation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
239
The slide highlights the ambiguity in the definition of 'cataplexy' used in the study protocol, leading to potential data reliability issues.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
240
The slide uses ClinicalTrials.gov record history to demonstrate a 'red flag' in trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
241
The slide uses red text for emphasis on specific criticisms (dose response, centre effect).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
242
The slide uses a CONSORT-style flow diagram to illustrate patient attrition in a clinical trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
243
The slide uses red boxes and text annotations to highlight specific data points (M6 for ESS, M12 for cataplexy) that contradict expected outcomes.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
244
The slide uses a comparative analysis of clinical trial data to challenge the validity of the HARMONY 3 results.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
245
The slide uses red text and boxes to emphasize the contradiction between the trial paper's claims and the EMA's findings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
246
This slide appears to be a transition or setup slide for a quote or testimonial that is currently missing or intentionally blank.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
247
The slide serves as a qualitative research summary based on 16 expert interviews.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
248
This slide presents a series of critical findings regarding market performance, competitive positioning, safety concerns, and marketing practices for the drug Wakix.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
249
The slide presents qualitative interview summaries as evidence of poor market reception.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
250
The slide presents anecdotal evidence from four specific prescribers, highlighting skepticism, reimbursement hurdles, and varying levels of adoption.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
251
The slide presents qualitative interview summaries highlighting drug discontinuation, safety concerns, and competitive disadvantages.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
252
The slide presents qualitative interview data from four distinct medical professionals, highlighting skepticism, lack of efficacy, and safety concerns.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
253
The slide presents a qualitative anecdote from a physician interview regarding drug safety.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
254
The slide uses direct quotes from a KOL to undermine the market potential of Wakix.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
255
The slide uses a Q&A format to present qualitative feedback from a medical expert.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
256
The slide uses direct quotes from a physician to highlight low adoption and skepticism.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
257
Includes highlighted text emphasizing the shift in sentiment from bullish to skeptical.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
258
The slide uses a Q&A format to highlight negative sentiment from a key opinion leader (KOL).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
259
The slide highlights a negative expert opinion on drug efficacy, contrasting it with the prescriber's own behavior.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
260
The slide uses a Q&A format to validate the negative sentiment expressed in the summary header.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
261
The slide presents qualitative feedback from a medical professional, highlighting skepticism and administrative barriers.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
262
The slide uses a Q&A format to validate the negative thesis regarding Wakix market performance.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
263
The slide uses a Q&A format to highlight the tightening reimbursement environment for a specific drug.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
264
Includes direct quotes from the physician regarding his clinical experience and frustrations with insurance paperwork.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
265
The slide uses a Q&A format to expose the physician's aggressive prescribing behavior and lack of clinical rigor.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
266
The slide highlights the physician's self-proclaimed influence and his personal relationship with sales reps, potentially exposing aggressive marketing tactics.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
267
The slide uses highlighted text to emphasize aggressive prescribing behavior and high patient penetration rates.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
268
The slide uses highlighted text to emphasize the doctor's skepticism regarding the drug's 'game-changer' status and the saturation of his patient base.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
269
The slide uses highlighted text to emphasize the doctor's lack of due diligence and surprise at the drug's high cost.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
270
Includes verbatim Q&A excerpts highlighting patient volume and discontinuation rates.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
271
The slide uses highlighted text to emphasize negative feedback from a key opinion leader.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
272
The slide uses a Q&A format to expose negative feedback regarding drug interactions and side effects.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
273
The slide uses a Q&A transcript format to validate the summary points provided at the top.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
274
The slide presents qualitative expert testimony regarding drug discontinuation rates.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
275
The slide uses direct quotes from a consultation call to challenge the drug's safety and efficacy profile.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
276
The slide contrasts the prescriber's relaxed attitude toward cardiac/hepatic monitoring with a specific, concerning anecdote about a patient experiencing uncontrollable anger.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
277
The slide uses a Q&A format to validate the prescriber's credentials and patient volume.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
278
The slide uses a Q&A format to present qualitative feedback from a specific physician.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
279
The slide highlights key negative sentiment regarding market saturation and physician adoption hurdles.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
280
The slide highlights potential regulatory/compliance risks (lack of monitoring) and commercial opacity (pricing) regarding the drug Wakix.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
281
The slide presents a transcript of an interview with a physician, highlighting negative clinical experience.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
282
The slide uses bolding and highlighting to emphasize negative sentiment from a key opinion leader.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
283
The slide uses a Q&A format to highlight a specific adverse event and the resulting loss of confidence in the drug's safety profile.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
284
The slide uses a Q&A format to document a specific adverse event case study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
285
The slide uses a Q&A transcript format to detail a specific medical case study involving drug safety concerns.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit